Correlation between T-Lymphocyte Subsets, Regulatory T Cells, and Hepatic Fibrosis in Patients with Nonalcoholic Fatty Liver

Xia Wang,1 Weiqin Li,1 Jiangfeng Fu,1 Yaping Ni,1 and Kaige Liu2

1The First Affiliated Hospital of Xi’an Medical College, Xi’an, Shanxi 710077, China
2Xi’an Medical College, Xi’an, Shanxi 710021, China

Correspondence should be addressed to Kaige Liu; liukaige222@xiyi.edu.cn

Received 13 May 2022; Accepted 27 June 2022; Published 31 July 2022

Academic Editor: Fenglin Liu

Copyright © 2022 Xia Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objective. The aim of this study is to assess the relationship between T-lymphocyte subsets, regulatory T cells (Treg), and hepatic fibrosis in patients with a nonalcoholic fatty liver disease (NAFLD).

Methods. A retrospective analysis was conducted on 64 NAFLD patients (research group) and 73 healthy subjects (control group) in our hospital from January 2020 to December 2021. T-lymphocyte subsets (Th17) and Treg, liver function (alanine aminotransferase (ALT), aspartate aminotransferase (AST)), hepatic fibrosis indexes (type III procollagen (PCIII), type IV collagen (CIV), laminin (LN), hyaluronic acid (HA)), inflammatory factors (high-sensitivity C-reactive protein (hs-CRP), interleukin 6 (IL-6), interleukin-8 (IL-8)), and oxidative stress (OS) response (superoxide dismutase (SOD), glutathione peroxidase (GSH-Px), malondialdehyde (MDA)) were tested. The relationship between Th17/Treg and the abovementioned indexes in NAFLD patients was analyzed. Results. In comparison to the control group, Th17 and Th17/Treg were higher in the research group (P < 0.05). In addition, liver function, liver fibrosis markers, inflammatory factors, and MDA were elevated, while SOD and GSH-Px decreased (P < 0.05). Subsequently, NAFLD patients were divided into groups A (Th17/Treg < 1.15, n = 33) and B (Th17/Treg ≥ 1.15, n = 31) based on their median Th17/Treg levels. It was seen that liver injury, hepatic fibrosis, inflammation, and OS in group A were more severe (P < 0.05). The Pearson correlation coefficient revealed that Th17/Treg was positively correlated with AST, ALT, PCIII, MDA, and inflammatory factors but negatively correlated with SOD and GSH-Px (P < 0.05).

1. Introduction

Nonalcoholic fatty liver disease (NAFLD) refers to a syndrome of metabolic stress-induced liver injury and is a highly prevalent chronic disease with a prevalence of approximately 6.0–35.0% worldwide [1]. In addition to directly causing decompensated cirrhosis, hepatocellular carcinoma, and transplanted liver recurrence, NAFLD can also affect the progression of other chronic liver diseases and be involved in the development of type 2 diabetes and atherosclerosis [2]. More serious cases may eventually develop into liver cirrhosis or hepatocellular carcinoma, and further compensation may lead to death of patients [3]. Recently, NAFLD has become a new challenge in contemporary medicine and its health risks are increasing [4]. Currently, the pathogenesis of NAFLD is not fully understood, and studies have shown that NAFLD is relevant to cardiovascular disease, chronic kidney disease, type 2 diabetes, obesity, and insulin resistance. For that reason, the treatment of NAFLD is still mainly based on long-term conservative treatment with glycemic and blood pressure control [5]. However, there is still a greater likelihood of hepatic fibrosis in NAFLD during this treatment, which signals an increased progression of NAFLD and a much higher likelihood of cirrhosis formation [6].

It is well known that human immune function, as a key link in the fight against various diseases, is accomplished by the interaction of lymphocytes, monocytes, and other related cells and their products [7]. In the case of hepatic fibrosis, the integrity of the immune function also greatly determines the proper functioning of the liver. For example, Zheng and Tian have suggested that the liver can mediate immune tolerance...
in humans [8], while Racanelli and Rehermann have found that the liver is the body’s first line of immune defense against invading pathogens [9]. Nevertheless, we find that studies related to changes in hepatic fibrosis and immune function in NAFLD patients are relatively rare.

Currently, therapeutic regimens targeting immune activation have been considered as a new direction in disease treatment such as plasmid invasion of the liver and hepatocellular carcinoma [10, 11]. Thus, it is vital to gain insights into the changes in immune function and liver fibrosis. This research study will analyze the relationship between T-lymphocyte subsets, regulatory T cells (Treg), and hepatic fibrosis in NAFLD patients, aiming to provide a new reference basis for future diagnosis and treatment.

2. Materials and Methods

2.1. Patient Data. Sixty-four NAFLD patients admitted to our hospital from January 2020 to December 2021 (research group) and 73 with health checkups during the same period (control group) were selected for retrospective analysis. The experiment was conducted in strict compliance with the Declaration of Helsinki, and all study subjects signed an informed consent form.

2.2. Inclusion and Exclusion Criteria

2.2.1. Research Group. Inclusion criteria: age > 18 years old; NAFID was confirmed in our hospital; Diagnostic criteria for NAFID [12]; no history of drinking alcohol or alcohol equivalent to less than 140 grams per week; women less than 70 grams per week; imaging findings of liver meet the diagnostic criteria of diffuse fatty liver, and no other reasons can be explained; thyroid function is normal; those with complete medical records. Exclusion Criteria: specific diseases that can cause fatty liver, such as viral hepatitis, drug-induced liver disease, Wilson’s disease, total parenteral nutrition, and autoimmune liver disease, are excluded. Those with other cardiovascular and cerebrovascular diseases, metabolic diseases, and tumors; those with severe infection; those with organ dysfunction and disorders; those with autoimmune defects; those with a history of NAFID treatment within 2 weeks before admission; pregnant and lactation patients.

2.2.2. Control Group. Healthy control subjects in our hospital; age > 18 years old; and no previous marked medical history. All physical examination results were normal.

2.3. Sample Collection. Altogether 6 mL of fasting venous blood was drawn on admission for both groups, respectively, and divided into two portions. A cell suspension of \(1 \times 10^7/\) mL was prepared for follow-up detection after mononuclear cells were isolated from lymphocytes. One copy was placed in a procoagulation tube and centrifuged (1505 × g, 4°C) for 20 min to obtain serum for subsequent testing.

2.4. Detection Methods. Cell suspensions were employed for flow cytometric detection of T-lymphocyte subpopulations (Th17) with a Treg assay. Serum was used to test the liver function by an automatic biochemical analyzer (alanine aminotransferase (ALT) and aspartate aminotransferase (AST)). Hepatic fibrosis indexes were tested by electrochemiluminescence (type III procollagen (PCHII), type IV collagen (CIV), laminin (LN), hyaluronic acid (HA)). Enzyme-linked immunosorbent assay (ELISA) was performed to detect inflammatory factors (high-sensitivity C-reactive protein (hs-CRP), interleukin-6 (IL-6), and interleukin-8 (IL-8)) and indicators of oxidative stress (superoxide dismutase (SOD), glutathione peroxidase (GSH-PX), and malondialdehyde (MDA)).

2.5. Outcome Measures. The outcome measures were as follows: (1) The differences of T-lymphocyte subsets, Treg, liver function, hepatic fibrosis, inflammatory factors, and OS reaction between groups. (2) The relationship between T-lymphocyte subsets, Treg, and the abovementioned indexes in NAFLD patients. (3) AST and ALT are the main indexes to judge the liver injury. AST >50, ALT >60 means that it is abnormally elevated, and the patient may have liver injury. The higher the value, the more serious the injury.

2.6. Statistical Methods. Data were statistically analyzed by SPSS22.0 software. The counting data were expressed by (n (%)) and assessed via the chi-square test. The measurement data were marked as (X ± s) and compared via independent sample t-test. The correlation was assessed by the Pearson correlation coefficient. \( P < 0.05 \) indicates that the difference is statistically marked.

3. Results

3.1. Comparison of Clinical Baseline Data. To ensure the reliability of the experimental results, we compared the baseline data of age, gender, smoking, and drinking between the groups. It manifested that there was no obvious difference \( (P > 0.05) \), which is comparable (Table 1).

3.2. Comparison of T-Lymphocyte Subsets and Treg. The results showed that the Th17 and Th17/Treg values in the research group were higher than those in the control group \( (P < 0.05) \). There was no significant difference in Treg values between the two groups \( (P > 0.05) \), indicating that the patients in the research group had a significant immune dysfunction (Figure 1).

3.3. Comparison of Liver Function and Hepatic Fibrosis. The serum liver function indexes AST, ALT, and liver fibrosis markers PCHII, CIV, LN, and HA in the research group were higher than those in the control group \( (P < 0.05) \), indicating that patients in the former had remarkable liver injury and hepatic fibrosis (Figure 2).
3.4. Comparison of Inflammatory Factors. The detection of inflammatory factors likewise demonstrated that hs-CRP, IL-6, and IL-8 in the serum of the research group were higher ($P < 0.05$), with a severe inflammation (Figure 3).

3.5. Comparison of OS Responses. The OS assay found that SOD and GSH-PX in the serum of the research group were lower than that of the control group, while MDA was higher ($P < 0.05$) (Figure 4).
3.6. Relationship between T-Lymphocyte Subsets, Treg, and Liver Function. Subsequently, we divided patients into group A (Th17/Treg < 1.15, n = 33) and group B (Th17/Treg ≥ 1.15, n = 31) based on their median Th17/Treg levels and compared their liver function test results. It turned out that the AST and ALT levels in group A were lower (P < 0.05). Moreover, the Pearson correlation coefficient analysis revealed a positive correlation between Th17/Treg and both AST (r = 0.597, P < 0.001) and ALT (r = 0.678, P < 0.001) (Figure 5).

3.7. Relationship between T-Lymphocyte Subsets, Treg, and Hepatic Fibrosis. Similarly, PCIII, CIV, LN, and HA in group A were lower than those in group B (P < 0.05). The Pearson correlation coefficient manifested a similar positive correlation between Th17/Treg and liver fibrosis markers (PCIII (r = 0.574), CIV (r = 0.732), LN (r = 0.580), and HA (r = 0.742)) (P < 0.05) (Figure 6).

3.8. Relationship between T-Lymphocyte Subsets, Treg, and Inflammatory Factors. It can be seen that hs-CRP, IL-6, and IL-8 in serum were likewise lower in group A than those in group B (P < 0.05). Furthermore, IL-6 (r = 0.454), and IL-8 (r = 0.404) (P < 0.05) (Figure 7).

3.9. Relationship between T-Lymphocyte Subsets, Treg, and Oxidative Stress Response. Finally, we discovered that patients in group A had higher SOD and GSH-PX and lower MDA levels compared to group B (P < 0.05). The Pearson correlation coefficient analysis revealed that the SOD levels were positively correlated with both ALT (r = 0.597, P < 0.001) and AST (r = 0.678, P < 0.001) (Figure 8).
Figure 6: Relationship between T-lymphocyte subsets, Treg, and hepatic fibrosis. (a) Comparison of liver fibrosis indicators. (b) Correlation of Th17/Treg with PCIII. (c) Correlation of Th17/Treg with CIV. (d) Correlation of Th17/Treg with LN. (e) Correlation of Th17/Treg with HA. * $P < 0.05$.

Figure 7: Relationship between T-lymphocyte subsets, Treg, and inflammatory factors. (a) Comparison of inflammatory factors. (b) Correlation of Th17/Treg with hs-CRP. (c) Correlation of Th17/Treg with IL-6. (d) Correlation of Th17/Treg with IL-8. * $P < 0.05$. 

Evidence-Based Complementary and Alternative Medicine 5
MDA than group B \((P < 0.05)\). Th17/Treg was negatively correlated with SOD \((r = -0.598)\) and GSH-PX \((r = 0.716)\), whereas it was positively correlated with MDA \((r = 0.715)\) \((P < 0.05)\) (Figure 8).

4. Discussion

NAFLD is one of the most familiar chronic liver diseases and the pathogenesis has not been fully elucidated. Most scholars believe that it is due to the accumulation of fat in the liver that leads to hepatocyte apoptosis and induces insulin resistance, which causes inflammation, hepatocyte damage, and fibrosis [13]. NAFLD is a major challenge for healthcare systems worldwide, with patients requiring prolonged specialized treatment that can progress to severe liver diseases and endanger their lives if neglected or mismanaged [14]. An in-depth understanding of the pathogenic mechanism of NAFLD is vital for finding new clinical treatment options. The immune function has been found to have an essential potential impact on the liver function, among which Th17/Treg, as one of the key indicators of human immunometabolic function, has been proven to be related to liver diseases such as chronic hepatitis B and acute liver injury [15, 16]. However, the relationship with NAFLD is not yet clear. Hence, the present study has crucial clinical implications by analyzing the effect of Th17/Treg on hepatic fibrosis in NAFLD.

First, to understand Th17/Treg in NAFLD, we tested Th17/Treg in patients compared with healthy physical examiners. Insomnia can lead to an abnormal liver function and a decreased immune function. Therefore, this study ensures that there is no statistical difference in the insomnia index between the study group and the control group, thus avoiding the experimental error caused by it. The results manifested that Th17 was higher in NAFLD patients compared to healthy persons, suggesting a close relationship between the two and NAFLD development and progression. Moreover, we can see a marked increase in Th17/Treg in NAFLD patients, which indicates that there is an obvious immune dysfunction in NAFLD. It is also consistent with the results of previous studies [17, 18]. Previous studies have pointed out that NAFLD is a complex process involving multiple factors, with lipid peroxidation, inflammatory factors, and natural immune imbalance playing important roles, among which the imbalance of Treg and Th17 cells is one of its pathological mechanisms [19]. Treg and Th17 cells are CD4+ T cells different from classical Th1 and Th2 cells. Treg cells mainly secrete IL-10 and TGF-β1, which improve hepatocyte inflammation by regulating other immune cell functions and thus controlling the body’s immune response, while Th17 cells mainly secrete inflammatory factors such as IL-17 and IL-22 and induce proinflammatory factors such as IL-6 and TNF-α, both of which antagonize each other in function and differentiation [20]. We can also fully confirm this after testing the inflammatory factors and OS responses in NAFLD patients and healthy persons. ALT and AST are the main indexes for clinical judgment of liver function damage, and their abnormal rise often indicates that patients have a liver injury, and the more they rise, the more serious the damage will be. PCIII, CIV, LN, and HA are the main indexes to judge patients’ liver fibrosis. The higher the value of these indexes, the higher the liver fibrosis. The results show that ALS, AST and PCIII, CIV, LN, and HA were all elevated in NAFLD patients, which is also consistent with the pathological manifestations of NAFLD [21, 22], indicating that patients already have a more obvious liver injury and hepatic fibrosis process at this time. Moreover, combining the above experiments and previous studies, we tentatively consider that due to the Th17/Treg imbalance in NAFLD patients, the liver undergoes a marked inflammation and OS, thus promoting the development of liver injury and hepatic fibrosis.

SOD, MDA, and GSH-PX are all important indexes to judge the degree of OS damage in patients. SOD and GSH-PX represent the body’s ability to clear free radicals, while MDA is closely related to the content of oxygen free radicals in the body. To further confirm the relationship between Th17/Treg and hepatic fibrosis, we divided patients into group A and B based on their Th17/Treg levels and found that the inflammatory factor levels and OS responses were higher in group A with higher Th17/Treg than those in group B. Moreover, patients in group A had more obvious liver injury and hepatic fibrosis conditions, verifying the relationship between the dysregulation of Th17/Treg and the pathological process of NAFLD. In addition, we found that Th17/Treg was positively correlated with AST, ALT, PCIII, CIV, LN, HA, MDA, and inflammatory factors, and negatively correlated with SOD and GSH-PX by the Pearson correlation coefficient, indicating that elevated Th17/Treg would promote liver injury, hepatic fibrosis, inflammation, and OS. It is well known that hepatic fibrosis appears after almost all chronic liver injuries and is a dynamic process in which various cells such as hepatic parenchymal cells, hepatic stellate cells, hepatic sinusoidal endothelial cells, and a series of cytokine interactions involved jointly mediate the process of hepatic fibrosis, which is a necessary stage of progression to cirrhosis and a common pathological process in many chronic liver diseases [23, 24]. Thus, we believe that due to the imbalance of Th17/Treg, hepatocytes can undergo degeneration and necrosis under the long-term inflammatory infiltration and oxidative reaction of lipids, forming a large amount of extracellular matrix (such as non-collagenous glycoproteins and proteoglycans), remaining collagen components, and accumulating in large amounts, which eventually cause fibrosis.

Of course, there are still many shortcomings. For example, due to the small sample size and single population, we need to include more subjects to improve the comprehensiveness of the findings in the subsequent study. Second, we also need to further confirm the pathway of action of Th17/Treg affecting hepatic fibrosis through basic experiments to provide more detailed clinical references. Finally, we need to follow the subjects included for a longer period of time to assess their long-term pathological changes.

In summary, Th17/Treg is associated with hepatic fibrosis in NAFLD patients, and Th17/Treg imbalance can promote inflammatory responses and OS in the liver,
thereby advancing the development of liver injury and hepatic fibrosis.

**Data Availability**

The data used to support the findings of this study can be obtained from the corresponding author upon reasonable request.

**Conflicts of Interest**

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as potential conflicts of interest.

**References**

[1] M. F. Abdelmalek, “Nonalcoholic fatty liver disease: another leap forward,” *Nature Reviews Gastroenterology & Hepatology*, vol. 18, no. 2, pp. 85-86, 2021.

[2] T. G. Cotter and M. Rinella, “Nonalcoholic fatty liver disease 2020: the state of the disease,” *Gastroenterology*, vol. 158, no. 7, pp. 1851–1864, 2020.

[3] L. Castera, M. Friedrich-Rust, and R. Loomba, “Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease,” *Gastroenterology*, vol. 156, no. 5, Article ID 1281.e4, 2019.

[4] S. A. Polyzos, J. Kountouras, and C. S. Mantzoros, “Obesity and nonalcoholic fatty liver disease: from pathophysiology to therapeutics,” *Metabolism*, vol. 92, pp. 82–97, 2019.

[5] I. Pierantonelli and G. Svegliati-Baroni, “Nonalcoholic fatty liver disease: basic pathogenetic mechanisms in the progression from NAFLD to NASH,” *Transplantation*, vol. 103, no. 1, pp. e1–e13, 2019.

[6] F. Bessone, M. V. Razorli, and M. G. Roma, “Molecular pathways of nonalcoholic fatty liver disease development and progression,” *Cellular and Molecular Life Sciences*, vol. 76, no. 1, pp. 99–128, 2019.

[7] P. Kubes and C. Jenne, “Immune responses in the liver,” *Annual Review of Immunology*, vol. 36, no. 1, pp. 247–277, 2018.

[8] M. Zheng and Z. Tian, “Liver-mediated adaptive immune tolerance,” *Frontiers in Immunology*, vol. 10, p. 2525, 2019.

[9] V. Racanelli and B. Rehermann, “The liver as an immunological organ,” *Hepatology*, vol. 43, no. S1, pp. S54–S62, 2006.

[10] D. F. Ruether, G. M. Schaub, P. M. Duengelhoef et al., “SARS-CoV2-specific humoral and T-cell immune response after second vaccination in liver cirrhosis and transplant patients,” *Clinical Gastroenterology and Hepatology*, vol. 20, no. 1, pp. 162–172.e9, 2022.

[11] C. Mao, M. J. Gorbet, A. Singh, A. Ranjan, and S. Fiering, “In situ vaccination with nanoparticles for cancer immunotherapy: understanding the immunology,” *International Journal of Hyperthermia*, vol. 37, no. 3, pp. 4–17, 2020.

[12] N. Chalasani, Z. Younossi, J. E. Lavine et al., “The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American association for the study of liver diseases,” *Hepatology*, vol. 67, no. 1, pp. 328–357, 2018.

[13] Y. C. Zhao, G. J. Zhao, Z. Chen, Z. G. She, J. Cai, and H. Li, “Nonalcoholic fatty liver disease: an emerging driver of hypertension,” *Hypertension*, vol. 75, no. 2, pp. 275–284, 2020.
[14] J. H. Zhou, J. J. Cai, Z. G. She, and H. L. Li, “Noninvasive evaluation of nonalcoholic fatty liver disease: current evidence and practice,” *World Journal of Gastroenterology*, vol. 25, no. 11, pp. 1307–1326, 2019.

[15] H. Mou, S. Wu, G. Zhao, and J. Wang, “Changes of Th17/Treg ratio in the transition of chronic hepatitis B to liver cirrhosis and correlations with liver function and inflammation,” *Experimental and Therapeutic Medicine*, vol. 17, no. 4, pp. 2963–2968, 2019.

[16] Y. Liu, L. Fan, Z. Cheng et al., “Fecal transplantation alleviates acute liver injury in mice through regulating Treg/Th17 cytokines balance,” *Scientific Reports*, vol. 11, no. 1, p. 1611, 2021.

[17] J. Behary, N. Amorim, X. T. Jiang et al., “Gut microbiota impact on the peripheral immune response in non-alcoholic fatty liver disease related hepatocellular carcinoma,” *Nature Communications*, vol. 12, no. 1, p. 187, 2021.

[18] H. Tilg, T. E. Adolph, M. Dudek, and P. Knolle, “Non-alcoholic fatty liver disease: the interplay between metabolism, microbes and immunity,” *Nature Metabolism*, vol. 3, no. 12, pp. 1596–1607, 2021.

[19] M. A. Van Herck, J. Weyler, W. J. Kwanten et al., “The differential roles of T cells in non-alcoholic fatty liver disease and obesity,” *Frontiers in Immunology*, vol. 10, p. 82, 2019.

[20] N. H. Tan, B. Chen, J. Peng, and S. Du, “Treg/Th17 cell balance in patients with hepatitis B virus-related acute-on-chronic liver failure at different disease stages,” *BioMed Research International*, vol. 2021, Article ID 9140602, 13 pages, 2021.

[21] W. P. Esler and K. K. Bence, “Metabolic targets in nonalcoholic fatty liver disease,” *Cellular and Molecular Gastroenterology and Hepatology*, vol. 8, no. 2, pp. 247–267, 2019.

[22] K. Pafili and M. Roden, “Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans,” *Molecular Metabolism*, vol. 50, Article ID 101122, 2021.

[23] R. F. Schwabe, I. Tabas, and U. B. Pajvani, “Mechanisms of fibrosis development in nonalcoholic steatohepatitis,” *Gastroenterology*, vol. 158, no. 7, pp. 1913–1928, 2020.

[24] C. H. Lee, W. K. Seto, D. T. W. Lui et al., “Circulating thrombospondin-2 as a novel fibrosis biomarker of nonalcoholic fatty liver disease in type 2 diabetes,” *Diabetes Care*, vol. 44, no. 9, pp. 2089–2097, 2021.